Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode

Stephen M. Strakowski, Jacqueline L. Johnson, Melissa P. DelBello, Robert M. Hamer, Alan I. Green, Mauricio Tohen, Jeffrey A. Lieberman, Ira Glick, Jayendra K. Patel, Jeffrey Lieberman, Diana Perkins, Joseph P. McEvoy, Cecil Charles, Richard Keefe, Robert B. Zipursky, Zafiris J. Daskalakis, Alan I. Green, Charles Nemeroff, Robin Murray, Tonmoy Sharma & 10 others Raquel E. Gur, Bruce Cohen, Franca Centorrino, R. S. Kahn, Wayne Goodman, John Kuldau, Anthony J. Rothschild, John De Quardo, Gary Tollefson, Todd Sanger

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives: Schizophrenia causes significant impairments of quality of life. As treatment approaches have advanced, more attention has been given to re-integrating patients into their psychosocial environments, rather than simply monitoring psychotic symptoms. The development of the second-generation antipsychotics raised hope that these medications would provide better quality of life improvement than conventional antipsychotics. This improvement is particularly relevant early in the course of schizophrenia. Methods: To address these considerations, improvements in measures of general health and social function (determined using the SF-36) were assessed in 195 patients with first-episode schizophrenia for up to one year following randomization to either olanzapine or haloperidol in a double blind clinical trial. We hypothesized that olanzapine would demonstrate better improvement on these measures than haloperidol. In order to test this hypothesis, we used a repeated measure model with SF-36 scores as the outcome, and treatment group, time, time2, time-by-treatment group interaction, and time2-by-treatment group interaction as fixed effects. Results: Both treatments demonstrated similar changes on the SF-36. Independent of treatment, patients demonstrated significant improvements in most of the SF-36 subscales, which approached normative scores by the end of one year of treatment. Forty-six of 100 olanzapine-treated patients and 37 of 95 haloperidol-treated patients completed the one year of this study (p < .4). Conclusions: These results suggest an important initial treatment goal for patients with new onset schizophrenic disorders, namely that they can expect to recover significant quality of life and social function at least initially in treatment.

Original languageEnglish
Pages (from-to)161-169
Number of pages9
JournalSchizophrenia Research
Volume78
Issue number2-3
DOIs
StatePublished - Oct 15 2005
Externally publishedYes

Fingerprint

olanzapine
Haloperidol
Quality of Life
Schizophrenia
Therapeutics
Antipsychotic Agents
Hope
Random Allocation
Quality Improvement

Keywords

  • First-episode psychosis
  • Functional outcome
  • Schizophrenia
  • SF-26

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Strakowski, S. M., Johnson, J. L., DelBello, M. P., Hamer, R. M., Green, A. I., Tohen, M., ... Sanger, T. (2005). Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research, 78(2-3), 161-169. https://doi.org/10.1016/j.schres.2005.04.017

Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. / Strakowski, Stephen M.; Johnson, Jacqueline L.; DelBello, Melissa P.; Hamer, Robert M.; Green, Alan I.; Tohen, Mauricio; Lieberman, Jeffrey A.; Glick, Ira; Patel, Jayendra K.; Lieberman, Jeffrey; Perkins, Diana; McEvoy, Joseph P.; Charles, Cecil; Keefe, Richard; Zipursky, Robert B.; Daskalakis, Zafiris J.; Green, Alan I.; Nemeroff, Charles; Murray, Robin; Sharma, Tonmoy; Gur, Raquel E.; Cohen, Bruce; Centorrino, Franca; Kahn, R. S.; Goodman, Wayne; Kuldau, John; Rothschild, Anthony J.; De Quardo, John; Tollefson, Gary; Sanger, Todd.

In: Schizophrenia Research, Vol. 78, No. 2-3, 15.10.2005, p. 161-169.

Research output: Contribution to journalArticle

Strakowski, SM, Johnson, JL, DelBello, MP, Hamer, RM, Green, AI, Tohen, M, Lieberman, JA, Glick, I, Patel, JK, Lieberman, J, Perkins, D, McEvoy, JP, Charles, C, Keefe, R, Zipursky, RB, Daskalakis, ZJ, Green, AI, Nemeroff, C, Murray, R, Sharma, T, Gur, RE, Cohen, B, Centorrino, F, Kahn, RS, Goodman, W, Kuldau, J, Rothschild, AJ, De Quardo, J, Tollefson, G & Sanger, T 2005, 'Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode', Schizophrenia Research, vol. 78, no. 2-3, pp. 161-169. https://doi.org/10.1016/j.schres.2005.04.017
Strakowski, Stephen M. ; Johnson, Jacqueline L. ; DelBello, Melissa P. ; Hamer, Robert M. ; Green, Alan I. ; Tohen, Mauricio ; Lieberman, Jeffrey A. ; Glick, Ira ; Patel, Jayendra K. ; Lieberman, Jeffrey ; Perkins, Diana ; McEvoy, Joseph P. ; Charles, Cecil ; Keefe, Richard ; Zipursky, Robert B. ; Daskalakis, Zafiris J. ; Green, Alan I. ; Nemeroff, Charles ; Murray, Robin ; Sharma, Tonmoy ; Gur, Raquel E. ; Cohen, Bruce ; Centorrino, Franca ; Kahn, R. S. ; Goodman, Wayne ; Kuldau, John ; Rothschild, Anthony J. ; De Quardo, John ; Tollefson, Gary ; Sanger, Todd. / Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. In: Schizophrenia Research. 2005 ; Vol. 78, No. 2-3. pp. 161-169.
@article{34628426c85048bc86de574544802cb9,
title = "Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode",
abstract = "Objectives: Schizophrenia causes significant impairments of quality of life. As treatment approaches have advanced, more attention has been given to re-integrating patients into their psychosocial environments, rather than simply monitoring psychotic symptoms. The development of the second-generation antipsychotics raised hope that these medications would provide better quality of life improvement than conventional antipsychotics. This improvement is particularly relevant early in the course of schizophrenia. Methods: To address these considerations, improvements in measures of general health and social function (determined using the SF-36) were assessed in 195 patients with first-episode schizophrenia for up to one year following randomization to either olanzapine or haloperidol in a double blind clinical trial. We hypothesized that olanzapine would demonstrate better improvement on these measures than haloperidol. In order to test this hypothesis, we used a repeated measure model with SF-36 scores as the outcome, and treatment group, time, time2, time-by-treatment group interaction, and time2-by-treatment group interaction as fixed effects. Results: Both treatments demonstrated similar changes on the SF-36. Independent of treatment, patients demonstrated significant improvements in most of the SF-36 subscales, which approached normative scores by the end of one year of treatment. Forty-six of 100 olanzapine-treated patients and 37 of 95 haloperidol-treated patients completed the one year of this study (p < .4). Conclusions: These results suggest an important initial treatment goal for patients with new onset schizophrenic disorders, namely that they can expect to recover significant quality of life and social function at least initially in treatment.",
keywords = "First-episode psychosis, Functional outcome, Schizophrenia, SF-26",
author = "Strakowski, {Stephen M.} and Johnson, {Jacqueline L.} and DelBello, {Melissa P.} and Hamer, {Robert M.} and Green, {Alan I.} and Mauricio Tohen and Lieberman, {Jeffrey A.} and Ira Glick and Patel, {Jayendra K.} and Jeffrey Lieberman and Diana Perkins and McEvoy, {Joseph P.} and Cecil Charles and Richard Keefe and Zipursky, {Robert B.} and Daskalakis, {Zafiris J.} and Green, {Alan I.} and Charles Nemeroff and Robin Murray and Tonmoy Sharma and Gur, {Raquel E.} and Bruce Cohen and Franca Centorrino and Kahn, {R. S.} and Wayne Goodman and John Kuldau and Rothschild, {Anthony J.} and {De Quardo}, John and Gary Tollefson and Todd Sanger",
year = "2005",
month = "10",
day = "15",
doi = "10.1016/j.schres.2005.04.017",
language = "English",
volume = "78",
pages = "161--169",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode

AU - Strakowski, Stephen M.

AU - Johnson, Jacqueline L.

AU - DelBello, Melissa P.

AU - Hamer, Robert M.

AU - Green, Alan I.

AU - Tohen, Mauricio

AU - Lieberman, Jeffrey A.

AU - Glick, Ira

AU - Patel, Jayendra K.

AU - Lieberman, Jeffrey

AU - Perkins, Diana

AU - McEvoy, Joseph P.

AU - Charles, Cecil

AU - Keefe, Richard

AU - Zipursky, Robert B.

AU - Daskalakis, Zafiris J.

AU - Green, Alan I.

AU - Nemeroff, Charles

AU - Murray, Robin

AU - Sharma, Tonmoy

AU - Gur, Raquel E.

AU - Cohen, Bruce

AU - Centorrino, Franca

AU - Kahn, R. S.

AU - Goodman, Wayne

AU - Kuldau, John

AU - Rothschild, Anthony J.

AU - De Quardo, John

AU - Tollefson, Gary

AU - Sanger, Todd

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Objectives: Schizophrenia causes significant impairments of quality of life. As treatment approaches have advanced, more attention has been given to re-integrating patients into their psychosocial environments, rather than simply monitoring psychotic symptoms. The development of the second-generation antipsychotics raised hope that these medications would provide better quality of life improvement than conventional antipsychotics. This improvement is particularly relevant early in the course of schizophrenia. Methods: To address these considerations, improvements in measures of general health and social function (determined using the SF-36) were assessed in 195 patients with first-episode schizophrenia for up to one year following randomization to either olanzapine or haloperidol in a double blind clinical trial. We hypothesized that olanzapine would demonstrate better improvement on these measures than haloperidol. In order to test this hypothesis, we used a repeated measure model with SF-36 scores as the outcome, and treatment group, time, time2, time-by-treatment group interaction, and time2-by-treatment group interaction as fixed effects. Results: Both treatments demonstrated similar changes on the SF-36. Independent of treatment, patients demonstrated significant improvements in most of the SF-36 subscales, which approached normative scores by the end of one year of treatment. Forty-six of 100 olanzapine-treated patients and 37 of 95 haloperidol-treated patients completed the one year of this study (p < .4). Conclusions: These results suggest an important initial treatment goal for patients with new onset schizophrenic disorders, namely that they can expect to recover significant quality of life and social function at least initially in treatment.

AB - Objectives: Schizophrenia causes significant impairments of quality of life. As treatment approaches have advanced, more attention has been given to re-integrating patients into their psychosocial environments, rather than simply monitoring psychotic symptoms. The development of the second-generation antipsychotics raised hope that these medications would provide better quality of life improvement than conventional antipsychotics. This improvement is particularly relevant early in the course of schizophrenia. Methods: To address these considerations, improvements in measures of general health and social function (determined using the SF-36) were assessed in 195 patients with first-episode schizophrenia for up to one year following randomization to either olanzapine or haloperidol in a double blind clinical trial. We hypothesized that olanzapine would demonstrate better improvement on these measures than haloperidol. In order to test this hypothesis, we used a repeated measure model with SF-36 scores as the outcome, and treatment group, time, time2, time-by-treatment group interaction, and time2-by-treatment group interaction as fixed effects. Results: Both treatments demonstrated similar changes on the SF-36. Independent of treatment, patients demonstrated significant improvements in most of the SF-36 subscales, which approached normative scores by the end of one year of treatment. Forty-six of 100 olanzapine-treated patients and 37 of 95 haloperidol-treated patients completed the one year of this study (p < .4). Conclusions: These results suggest an important initial treatment goal for patients with new onset schizophrenic disorders, namely that they can expect to recover significant quality of life and social function at least initially in treatment.

KW - First-episode psychosis

KW - Functional outcome

KW - Schizophrenia

KW - SF-26

UR - http://www.scopus.com/inward/record.url?scp=24344477059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344477059&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2005.04.017

DO - 10.1016/j.schres.2005.04.017

M3 - Article

VL - 78

SP - 161

EP - 169

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 2-3

ER -